Inhibikase director granted 155,000 stock options

Inhibikase Therapeutics, Inc. director Arvind Kush received a grant of stock options covering 155,000 shares of common stock.

Rhea-AI Filing Summary

Inhibikase Therapeutics, Inc. director Arvind Kush received a grant of stock options covering 155,000 shares of common stock. The options have an exercise price of $1.91 per share and were awarded at no cost to the director.

The options vest on the earlier of June 26, 2027 or the day prior to the company’s next annual meeting of stockholders, subject to his continued service as a director. Following this grant, he holds stock options for 155,000 underlying shares directly.

Insights

Equity compensation analyst

Director received a routine stock option grant for 155,000 shares at $1.91.

The filing shows director Arvind Kush receiving stock options for 155,000 shares of Inhibikase Therapeutics common stock at an exercise price of $1.91 per share. This is coded as a grant/award, indicating compensation rather than an open-market trade.

The options vest on the earlier of June 26, 2027 or the day before the next annual stockholder meeting, contingent on continued board service. This time-based vesting aligns the director’s incentives with longer-term company performance while encouraging ongoing service.

No sales or exercises are reported, and there are no remaining derivative positions listed beyond this grant. From an investor perspective, this appears to be a standard equity incentive award, not a directional signal about the company’s near-term prospects.

Insider Trade Summary

Grant/Award: 155,000 shares

Grant/Award 1 txn

Insider Kush Arvind

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	155,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 155,000 contracts (Direct)

Footnotes (1)

1. F1. The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Key Figures

Option shares granted: 155,000 shares Exercise price: $1.91 per share Shares underlying options after grant: 155,000 shares +2 more

5 metrics

Option shares granted 155,000 shares Stock Option (Right to Buy) grant to director

Exercise price $1.91 per share Exercise price of newly granted stock options

Shares underlying options after grant 155,000 shares Total underlying common shares following the transaction

Option expiration date June 26, 2036 Expiration of stock option grant

Latest vesting date June 26, 2027 Latest vesting date, or earlier before next annual meeting

Key Terms

Stock Option (Right to Buy), Common Stock, exercise price, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: 1.9100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-26T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

What did Inhibikase Therapeutics (IKT) director Arvind Kush report in this Form 4?

Director Arvind Kush reported receiving a stock option grant for 155,000 shares of Inhibikase Therapeutics common stock. The options were granted as compensation and not purchased in the open market.

How many Inhibikase Therapeutics (IKT) shares are covered by the new stock options?

The new stock option grant covers 155,000 shares of Inhibikase Therapeutics common stock. Following the grant, the Form 4 shows total options covering 155,000 underlying shares held directly by the director.

What is the exercise price of the Inhibikase Therapeutics (IKT) options granted to Arvind Kush?

The stock options granted to director Arvind Kush have an exercise price of $1.91 per share. This is the price he would pay per share to convert the options into Inhibikase common stock in the future.

When do Arvind Kush’s Inhibikase Therapeutics (IKT) stock options vest?

The options will vest on the earlier of June 26, 2027 or the day prior to Inhibikase Therapeutics’ next annual meeting of stockholders. Vesting is conditioned on his continued service as a director through that date.

Does this Inhibikase Therapeutics (IKT) Form 4 show any stock sales by Arvind Kush?

No, the Form 4 reports only a stock option grant to director Arvind Kush. It does not show any open-market purchases, sales, or option exercises, indicating a routine compensation award rather than a trading decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kush Arvind

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DELAWARE 19801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.91	06/26/2026		A		155,000		(1)	06/26/2036	Common Stock	155,000	$0	155,000	D

Explanation of Responses:

1. The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

	/s/ Mark Iwicki, attorney-in-fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)